On February 11, 2025, Jiangsu Yiling Pharmaceutical Development Co., Ltd. (hereinafter referred to as "Jiangsu Yiling") successfully held a design bidding meeting for its high-end biopharmaceutical preparation production project at Beijing Huayaoketron Pharmaceutical Technology Development Co., Ltd. (hereinafter referred to as "Huayao Ketron"), marking the official commencement of the project.

The project is located in the Jinhu Economic and Technological Development Zone, Huai'an City, Jiangsu Province, covering an area of 57 mu. It is planned to construct six production lines for oral solids, lyophilized powder injections, BFS (Blow-Fill-Seal), oral liquids, sprays, and large-volume infusions. The project is divided into two phases. The first phase will cover a construction area of 15,000 ㎡, primarily consisting of an integrated production workshop, various warehouses, utility engineering, and a quality inspection center. The second phase will cover a construction area of 26,000 ㎡, mainly comprising an integrated production workshop and an office-quality inspection complex building.

The  bidding meeting attracted six well-known pharmaceutical design institutes from across the country to participate, including China National Pharmaceutical Engineering Co., Ltd., the East China Branch of the 11th Institute of the Information Industry Electronics, Hebei Aoheng Engineering Design and Consulting Co., Ltd., Shanghai Fred-Pharma Intelligent Engineering Co., Ltd., the Suzhou Design and Research Institute of Zhongheng Design Group, and Sichuan Provincial Institute of Pharmaceutical Design Co., Ltd. After intense competition and rigorous evaluation by the expert panel, Sichuan Provincial Institute of Pharmaceutical Design Co., Ltd. ultimately secured the bid due to its extensive project experience, outstanding design proposal, and competitive pricing.

This project represents a significant strategic move for Huayaoketron in Jiangsu Province. Upon completion, it will serve as a crucial pillar for the company's growth and contribute positively to the local economic development and the advancement of the biopharmaceutical industry.